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Abstract 
Rationale 
Antipsychotic polypharmacy (APP) is commonly used in schizophrenia despite a lack of 
robust evidence for efficacy, as well as evidence of increased rates of adverse drug reactions 
(ADR’s) and mortality. 
Objectives  
We sought to examine polypharmacy and use of other adjunctive medications in patients with 
treatment resistant schizophrenic disorders (ICD-10 diagnoses F20-29)schizophrenia 
immediately prior to clozapine initiation, and to investigate clinical and sociodemographic 
factors associated with polypharmacy use in this setting. 
Methods  
Analysis of case notes from 310 patients receiving their first course of clozapine at the South 
London and Maudsley NHS Trust (SLaM) was undertaken using the Clinical Record 
Interactive Search (CRIS) case register.  Medication taken immediately prior to clozapine 
initiation was recorded, and global clinical severity was assessed at time points throughout 
the year prior to medication assessment using the Clinical Global Impression - Severity scale 
(CGI-S). Logistic regression was used to investigate factors associated with antipsychotic 
polypharmacy. 
Results 
The point prevalence of antipsychotic polypharmacy prior to clozapine initiation was 13.6% 
(n=42), with 32.6% of subjects prescribed adjuvant psychotropic medications.  APP was 
associated with increasing number of adjuvant medications (odds ratio [OR] 1.97, 95% 
confidence interval [CI] 1.27 – 3.06), concurrent depot antipsychotic prescription (OR 2.64, 
CI 1.24 – 5.62), concurrent antidepressant prescription (OR 4.40, CI 1.82 – 10.63), and a 
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CGI-S over the previous year within the two middle quartiles (Quartile 2 vs. 1 OR 6.19, CI 
1.81 – 21.10, Quartile 3 vs. 1 OR 4.45, CI 1.29 – 15.37 Quartile 4 vs. 1 OR 1.88, CI 0.45 – 
7.13).   
Conclusions 
Antipsychotic polypharmacy and augmentation of antipsychotics with antidepressants, mood 
stabilisers, and benzodiazepines are being employed in treatment resistant schizophrenia prior 
to clozapine.  The conservative antipsychotic polypharmacy rate observed may have been 
influenced by an initiative within SLaM that reduced polypharmacy rates during the study 
window (Mace and Taylor, 2015). Efforts to reduce the use of poorly evidenced prescribing 
should focus on adjuvant medications as well as antipsychotic polypharmacy.    
 
Key Words: schizophrenia, polypharmacy, antipsychotic, clozapine, treatment resistant, 
augmentation, adjunctive, antidepressant, mood stabiliser, benzodiazepine. 
 
Abbreviations: ADR’s – adverse drug reactions, APP – antipsychotic polypharmacy, CGI-S 
– Clinical Global Impression Severity scale CRIS – Clinical Record Interactive Search, 
GATE – general architecture for text engineering, MHA – Mental Health Act, NHS – 
National Health Service, NICE - National Institute for Health and Care Excellence, POMH – 
Prescribing Observatory for Mental Health, SLaM – South London and Maudsley NHS Trust, 
SMI – serious mental illness. 
 
Antipsychotic polypharmacy, the concurrent use of two or more antipsychotics, remains 
common in the UK with 38% of all psychiatric inpatients and 16% of those with 
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schizophrenia living in the community prescribed multiple antipsychotics (Mace and Taylor, 
2015; Patel et al. 2014).  Analysis of the national Danish health registers demonstrated wide 
geographical variation in polypharmacy utilisation, and whilst its use decreased between 
2006 and 2012, it remains more prevalent than in 1996 (Sneider et al., 2015).    
A number of factors contribute to the use of APP.  From the limited number of studies that 
examine antipsychotic polypharmacy in schizophrenia, individuals with treatment resistance 
,(the failure to respond to adequate courses of two different antipsychotics,) show much 
higher rates of APP (Schmidt-Kraepelin et al., 2013).  Ineffectual control of symptoms may 
lead to clinicians prescribing multiple antipsychotics, and improvement during cross-titration 
between antipsychotics may lead to long-term prescribing of both drugs.  Additional 
antipsychotics, sometimes used initially as ‘as required’ medication, may be introduced as 
regular medication for patients with aggression or short-term distress and agitation, leading to 
long-term use.  Grech et al. (2014) found 39% of patients were prescribed long-term 
polypharmacy (> 6 months) after 0 or 1 monotherapy trials, and that less than half of those 
prescribed polypharmacy had been trialled on clozapine. 
Despite the widespread use of antipsychotic polypharmacy evidence regarding efficacy over 
monotherapy in treatment resistance is both limited and equivocal, particularly with regard 
tofor non-clozapine combinations of polypharmacy.  Clozapine monotherapy has been 
demonstrated in individual studies and meta-analyses to reduce symptoms in treatment 
resistant patients, and is more efficacious than other second generation antipsychotics (Lewis 
et al, 2006; McEvoy et al., 2006; Wahlbeck et al., 1999). Small open-label trials have 
demonstrated varying levels of symptom improvement when non-clozapine combinations of 
APP were utilised (Lerner et al., 2000; Lerner et al., 2005; Potkin et al., 2002; Zink et al., 
2004,). However, a meta-analysis of 19 polypharmacy trials by Correll et al (2009) suggested 
that publication bias may have been present, with larger studies showing smaller effects and 
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the greatest effect evident when clozapine was included in the polypharmacy regimen. In 
particular, a large scale randomised controlled trial with 323 subjects found no improvement 
in symptoms when adjunctive aripiprazole or placebo were used in combination with either 
risperidone or quetiapine (Kane et al., 2009).  Meanwhile, some studies investigating 
augmentation of clozapine have demonstrated efficacy in positive symptom reduction 
(Muscatello et al., 2011; Josiassen et al, 2005), whilst others suggest the adjunctive use of 
aripiprazole can reduce metabolic side effects (Henderson et al, 2006).  In addition to 
questionable efficacy APP is associated with an increase in adverse drug reactions and 
hospitalisation (Centorrino et al., 2004), mortality (Waddington et al., 1998), and higher 
antipsychotic doses (Roh et al., 2014).  At s such therepresent there is insufficient evidence to 
support the use of any particular combination of non-clozapine antipsychotics.   
As such,In view of the lack of evidence for polypharmacy, Nnational efforts have been made 
to reduce polypharmacy in the UK since 2009 when the National Institute for Health and 
Care Excellence (NICE) issued guidance recommending the avoidance of polypharmacy 
except for the augmentation of clozapine in treatment resistance resistant patients who are 
unresponsive to clozapine alone.  Despite this, existing research suggests that this guidance 
has not been fully incorporated into clinical practice (Grech and Taylor, 2012). A systematic 
review concluded that careful switching from polypharmacy to monotherapy is feasible for 
most patients (Tani et al, 2013),, with but a large scale quality improvement program in the 
UK demonstrating demonstrated little change in polypharmacy rates with a baseline rate of 
43% amongst adult in-patients, and a re-audit rate of 39% (Paton et al., 2008).  Additionally, 
Howes et al. (2012) reported the prescription of clozapine was preceded by a mean 
theoretical delay of 47.7 months from when patients were first eligible for clozapine therapy, 
with 36.2% of patients receiving antipsychotic polypharmacy during this time. 
7 
 
Evidence regarding the efficacy of adjunctive antidepressants or mood stabilisers is also 
inconclusive ( Leucht et al., 2007; Rummel et al., 2006; Schwarz et al., 2008; Sepehry et al., 
2007), whilst benzodiazepines have been found to have no effect beyond short term sedation. 
(Volz et al., 2007). In addition to concerns regarding efficacy there are not enough data 
regarding adverse effects and long-term safety to recommend any of these adjunctive 
strategies for routine clinical use.   
It remains unclear how current evidence and guidance for antipsychotic polypharmacy in 
adults with treatment resistant schizophrenia are applied clinically. There are very few UK 
based naturalistic studies of APP in schizophrenia, and, as yet, no detailed examination of the 
sociodemographic and clinical predictors of non-clozapine antipsychotic polypharmacy in 
treatment resistant patients.  Additionally, to date no studies have investigated the use of both 
APP and augmentation with other classes of psychotropic drugs concurrently.   
So that psychopharmacological prescribing practices are better understood in treatment 
resistant schizophrenia we sought to investigate the use of antipsychotic polypharmacy and 
the use of antipsychotic augmentation with mood stabilisers, antidepressants, and 
benzodiazepines. Using a retrospective cohort design, in a sample of patients with treatment 
resistant schizophrenia, we examined the sociodemographic and clinical factors associated 
with polypharmacy prior to first-ever clozapine use.    
 
Methods 
Study setting 
The cohort was identified within the South London and Maudsley (SLaM) Biomedical 
Research Council Case Register.  SLaM is an NHS mental health trust that provides 
8 
 
secondary mental health services to a population of 1.2 million in the boroughs of Lambeth, 
Southwark, Lewisham and Croydon in South-East London, a population where age, gender, 
education, and levels of social deprivation are comparable to the wider population of London 
(Stewart et al., 2009).  The Clinical Record Interactive Search (CRIS) system, described in 
detail elsewhere (Stewart et al., 2009), allows researchers to access de-identified copies of 
patient’s electronic health records which have been in use across the trust since 2006.  A 
general architecture for text engineering application within CRIS was used to identify 
patients who fulfilled the inclusion criteria for this study (Fig. 1).  Eligibility was then 
manually confirmed by accessing full-text anonymised case notes in the user interface of 
CRIS. 
 
310 patients were eligible for inclusion (Fig. 1). Individuals aged 18 – 65 with an ICD-10 
F20-F29 diagnosis and who were prescribed clozapine for the first time between 1st January 
2007 and 31st December 2011 were included.  Patients Subjects were receiving care as either 
inpatients or outpatients under secondary mental health services provided by SLaM.  National 
patients referred from out of area for clozapine initiation were excluded as they are not 
representative of the study population and frequently lacked data on prescribing prior to 
clozapine initiation. 
Fig. 1 Cohort selection 
[Insert Figure 1] 
Outcome measures 
The main outcome measure in this study was use of antipsychotic polypharmacy at a single 
time point immediately prior to clozapine initiation in those with an ICD-10 F20 - F29 
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diagnosis.  Additionally, the use of adjunctive antidepressants, mood stabilisers, and 
benzodiazepines was assessed.  A retrospective analysis of full-text anonymised case notes 
(inpatient and community notes, correspondence between clinicians and external agencies) 
was undertaken within the CRIS system, and medications prescribed were manually 
recorded, taken from the clinical entries closest in time to clozapine initiation that contained 
sufficient information.  Antipsychotics, mood stabilisers, antidepressants and 
benzodiazepines prescribed for regular use were recorded along with route of administration.  
Antipsychotic polypharmacy was defined as the concurrent use of more than one regular 
antipsychotic drug.  In subjects where no antipsychotic prescription prior to clozapine 
initiation was evident in the immediately preceding case notes, evaluation of the previous 6 
months case notes were undertaken to confirm subjects were not receiving antipsychotics. 13 
patients were prescribed both oral and depot risperidone, and these patients were not included 
in the polypharmacy group, since this practice is recommended during risperidone depot 
initiation. 
Explanatory variables 
The main factors of interest in this study were clinical severity, concurrent use of adjuvant 
psychoactive medications, and sociodemographic factors.  In order to evaluate the 
relationship between polypharmacy use and clinical severity, manual analysis of case notes in 
the CRIS system was undertaken using the Clinical Global Impression Severity scale (CGI-S) 
to assess symptomatology and functioning immediately prior to clozapine initiation, as well 
as at 1, 3, 6, 9, and 12 months prior to clozapine therapy.  Average CGI-S over the year prior 
to medication data collection was calculated for each patient.  Case notes dated up to the 
midpoint between time points were used when assessing CGI-S to ensure an accurate 
reflection of psychopathology over the year was obtained.  For example, entries from 4.5 
months to 7.5 months were eligible for use in assessing the 6 month time point. A variety of 
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source material was used for each assessment to allow both symptoms and social functioning 
to be assessed, (ward round notes, nursing notes, community notes, correspondence) in 
addition to minimising potential bias from individual sources.  Inter-rater reliability for CGI-
S rating was calculated using two-way mixed effect model intra-class correlation coefficients.  
The absolute individual intra-class correlation coefficient for all four raters (JVT, JMC, SEL, 
JD) was 0.71, indicating substantial agreement.  Data regarding the use of adjuvant 
psychoactive medications was collected at a single time point for each patient prior to 
clozapine initiation, as described above.  Number of adjuvant medications was defined as the 
total number of antidepressants, mood stabilisers, and regular benzodiazepines prescribed to 
each patient in addition to antipsychotics.   
Age, gender, ethnicity, ICD-10 diagnosis, and whether patients were detained under the 
mental health act (MHA) at clozapine initiation were extracted from structured fields within 
CRIS. Age was defined as age at start of clozapine treatment.  Ethnicity was categorised into 
three groups – White British or other white background, African Caribbean or other black 
background, and other.  Social deprivation was estimated using the ‘Index of Multiple 
Deprivation’, with area-level deprivation scores available in CRIS based on postal codes and 
data from the 2007 UK census, and was categorised into high, medium, and low levels of 
deprivation.  The Index of Multiple Deprivation is calculated based upon employment, 
health, education, housing, crime, and environment.  Polypharmacy point prevalence in 
SLaM inpatients was calculated from audit data supplied by SLaM pharmacy and the 
Prescribing Observatory for Mental Health (POMH) for 2007, 2008, 2009, and 2012 after 
exclusion of patients prescribed clozapine to aid comparability.  Some categories of 
explanatory variables have been merged in line with confidentiality protocols required for use 
of the CRIS dataset.  
Statistical analysis 
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Crude analysis of factors associated with antipsychotic polypharmacy prior to clozapine 
initiation was carried out using Pearson’s χ2 for categorical variables and logistic regression 
for continuous variables. Logistic regression was used for multivariable analysis. The logistic 
regression model was adjusted for all variables that appear within Table 2, with the exception 
of ‘increasing number of adjunctive medications’ as this was highly correlated with mood 
stabiliser, antidepressant, and benzodiazepine prescription.  Likelihood ratio tests indicated 
that it was appropriate to include average CGI-S over the year prior to medication review as 
an ordered categorical variable (quartiles), and age as a continuous variable.  Stata 13 was 
used for all statistical analysis.   
Ethical approval 
Ethical approval for the use of CRIS as a research dataset was given by Oxfordshire Research 
Ethics Committee C (08/H0606/71). Permission for this study was granted by the CRIS 
oversight committee.  
 
Results 
64.5% of the cohort was male, and 91% of subjects had an ICD-10 diagnosis of 
Schizophrenia (F25.0).   Black Africans and Caribbeans comprised 47.7% of the cohort 
whilst White subjects comprised 40.0%. 
Antipsychotic polypharmacy 
13.6% of patients (n=42) were prescribed antipsychotic polypharmacy immediately prior to 
clozapine initiation (Table 2), of whom 22 were prescribed two oral antipsychotics and 17 
were prescribed concurrent oral and depot medication.  Amisulpride combined with 
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quetiapine was the most commonly prescribed individual regimen of polypharmacy (n=6), 
with 28 different combinations of antipsychotics used across the 42 instances of APP.  
Factors associated with antipsychotic polypharmacy 
Increasing number of adjuvant medications (antidepressants, mood, stabilisers, 
benzodiazepines) was associated with polypharmacy (Table 2, odds ratio [OR] 1.97, 95% 
confidence interval [CI] 1.27 – 3.06).  Multivariable analysis indicated that individuals with 
an average CGI-S within the two middle quartiles (4.33 – 5.17) over the year prior to 
clozapine initiation were more likely to be prescribed polypharmacy prior to clozapine 
initiation (Table 2, Quartile 2 vs. Q1 OR 6.19, CI 1.81 – 21.10, Q3 vs. Q1 OR 4.45, CI 1.29 – 
15.37, Q4 vs. Q1 OR 1.88, CI 0.45 – 7.13).  Additionally, the prescription of antidepressants 
(OR 4.40, CI 1.82 – 10.63), and depot preparations of antipsychotics (OR 2.64, CI 1.24 – 
5.62) were associated with increased use of APP, whilst the prescription of mood stabilisers 
and benzodiazepines were not.  Age, gender, ethnicity, diagnosis, detention under the MHA 
at clozapine initiation, and socioeconomic status were not significantly associated with 
polypharmacy.  APP decreased year on year throughout the study window from 18.2% 2007 
to 11.4% in 2011.  These results are in line with the reduction in polypharmacy across the 
trust due to the quality improvement program implemented within SLaM between 2006 and 
2012 which aimed to reduce antipsychotic polypharmacy and high dose prescribing (Fig. 2). 
Adjuvant medication 
32.6% of patients (n=101) were prescribed 1 or more adjuvant medications (mood stabilisers, 
antidepressants, benzodiazepines) in addition to antipsychotics (Table 1).  Sodium valproate 
(n=27) and lithium (n=7) were the most frequently prescribed adjunctive mood stabilisers 
(11.9% of cohort, n=37), whilst citalopram (n=17) and mirtazapine (n=8) were the most 
commonly prescribed antidepressants (15.2% of cohort, n=47).  Regular benzodiazepines 
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were prescribed to 11.6% (n=36), with clonazepam (n=23) used more frequently than 
diazepam (n=13). 
Monotherapy 
60.0% of patients were prescribed oral monotherapy, with olanzapine (n=68, 36.6% of oral 
monotherapy) and risperidone (n=44, 23.4% of oral monotherapy) the most commonly 
prescribed drugs.  Depot monotherapy was prescribed to 18.7% of patients, with 
zuclopenthixol decanoate (n=19, 32.7% of all depot monotherapy) and risperidone depot 
(n=13, 22.4% of all depot monotherapy) most commonly utilised.  Additionally, 4.2% of 
patients (n=13) were prescribed both depot and oral risperidone.  Of 11 patients who were 
prescribed no antipsychotics prior to clozapine initiation, seven were taking no psychoactive 
medication at all whilst the remainder were prescribed either mood stabilisers or 
antidepressants.     
Table 1 – Sample characteristics 
Variables Number of individuals (%) 
Total 310 (100) 
 
Demographic variables 
Gender  
Male 200 (64.5) 
Female 110 (35.5) 
Age  
<20 10 (3.2) 
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20-29 104 (33.6) 
30-39 77 (24.8) 
40-49 82 (26.5) 
50-59 28 (9.0) 
60-65 9 (2.9) 
Ethnicity  
White 124 (40.0) 
Black African / Caribbean 148 (47.7) 
Other 38 (12.3) 
Diagnosis  
Schizophrenia (F20) 282 (91.0) 
Schizoaffective disorder (F25) 18 (5.8) 
Other F20-29 diagnosis 10 (3.2) 
Detained under MHA at clozapine 
initiation 
 
Detained 156 (50.3) 
Not Detained 154 (49.7) 
Social deprivation index  
Low 82 (26.5) 
Medium 110 (35.5) 
High 98 (31.5) 
Unknown 20 (6.5) 
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Medication prescribed immediately prior to clozapine initiation 
Antipsychotic use  
Polypharmacy 42 (13.5) 
Monotherapy 257 (83.0) 
No antipsychotic 11 (3.5) 
Antidepressant use  
Antidepressant(s) 47 (15.2) 
No antidepressant 263 (84.8) 
Mood stabiliser use  
Mood stabiliser(s) 37 (11.9) 
No mood stabiliser 273 (88.1) 
Benzodiazepine use  
Benzodiazepine(s) 36 (11.6) 
No benzodiazepine 274 (88.4) 
Number of adjunctivea medications prescribed 
0 209 (67.4) 
1 81 (26.1) 
2 or more 20 (6.5) 
 
Average CGI-Sb in the year prior to clozapine initiation (quartiles) 
Q1 (2.00 – 4.33)  76 (24.5) 
Q2 (4.33 – 4.71)  79 (25.5) 
Q3 (4.71 – 5.17) 69 (22.3) 
Q4 (5.17 – 6.33) 86 (27.7) 
aAdjunctive medications defined as any anti-depressant, mood stabiliser, or benzodiazepine. 
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bIncreasing CGI-S denotes worsening global clinical severity. 
Table 2 – Crude analysis (χ2) and multivariate analysis (logistic regression) of factors 
associated with antipsychotic polypharmacy immediately prior to clozapine initiation 
Variable Crude OR (95% 
CI) 
Fully adjusted ORa 
(95% CI) 
 
Age 1.01 (0.98 – 1.04) 1.02 (0.98 – 1.05) 
 
Gender Male reference reference 
Female 1.01 (0.51 – 1.99) 0.91 (0.41 – 2.00) 
 
Ethnicity White reference reference 
Black 1.18 (0.59 – 2.36) 1.47 (0.63 – 3.47) 
Other 0.79 (0.25 – 2.54) 1.17 (0.32 – 4.47) 
 
Diagnosis Schizophrenia reference reference 
Schizoaffective 
disorder 
1.28 (0.35 – 4.65) 1.52 (0.68 – 3.50)  
Other F20-29 
diagnosis 
0.71 (0.09 – 5.80) 0.76 (0.08 – 7.80) 
 
Detained under MHA at 
clozapine initiation 
Not detained reference reference 
Detained 1.10 (0.57 – 2.11) 1.54 (0.67 – 3.50) 
 
17 
 
Social deprivation index Low reference reference 
Medium 1.13 (0.53 – 2.44) 1.24 (0.52 – 2.95) 
High 0.62 (0.26 – 1.50) 0.55 (0.21 – 1.45) 
 
Average CGI-S over year 
prior to medication review 
Quartile 1 (least 
severe) 
reference reference 
 Quartile 2 4.94 (1.58 – 
15.45) 
6.19 (1.81 – 21.10) 
 Quartile 3 4.18 (1.29 – 
13.51) 
4.45 (1.29 – 15.37) 
 Quartile 4 (most 
severe) 
1.85 (0.53 – 6.39) 1.88 (0.45 – 7.13) 
 
Mood stabiliser prescribed 1.59 (0.65 – 3.89) 1.37 (0.49 – 3.85) 
Antidepressant prescribed 3.09 (1.46 – 6.51) 4.40 (1.82 – 10.63) 
Benzodiazepine prescribed 2.01 (0.85 – 4.78) 2.47 (0.92 – 6.66) 
Depot antipsychotic prescribed 2.12 (1.09 – 4.14) 2.64 (1.24 – 5.62) 
Number of adjunctiveb medications 1.97 (1.27 – 3.06)  
aAdjusted for all variables that appear within the table with the exception of number of 
adjunctive medications which was highly correlated with mood stabiliser, antidepressant, and 
benzodiazepine prescription. 
bAdjunctive medications defined as any anti-depressant, mood stabiliser, or regular 
benzodiazepine.  
Fig. 2 Antipsychotic polypharmacy rate by year in cohort vs. SLaM inpatients 
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[Insert Figure 2] 
Discussion 
Summary of main findings 
The point prevalence of antipsychotic polypharmacy prior to clozapine initiation was 13.5% 
within our cohort of treatment resistant adults, with 28 different combinations of 
polypharmacy prescribed.  The use of antidepressants, mood stabilisers, and regular 
benzodiazepines was common with 32.6% of patients prescribed at least one of these 
medications, and antipsychotic polypharmacy was associated with increasing number of 
adjuvant medications prescribed.  Specifically, the prescription of antidepressants and depot 
antipsychotics were strongly associated with antipsychotic polypharmacy, whilst no 
association was evident between APP and the prescription of benzodiazepines or mood 
stabilisers.  Subjects whose average CGI-S was within the two middle quartiles were much 
more likely to be prescribed polypharmacy than subjects whose CGI-S was within either the 
least or more severe quartile.  No association was found between antipsychotic polypharmacy 
and any sociodemographic factors investigated. 
Comparison to other studies 
Our findings add to previous evidence that polypharmacy is being used inappropriately prior 
to clozapine, delaying use of this gold standard medication.  Whilst we report a point 
prevalence of polypharmacy prior to clozapine initiation, prescription surveys undertaken in 
SLaM during 2003 and 2012 note lifetime prevalence rates of antipsychotic polypharmacy 
prior to clozapine initiation of 65% and 32.6% respectively (Taylor et al., 2003; Howes et al., 
2012), with Howes et al. reporting that this contributed to a mean theoretical delay to 
clozapine initiation of 47.7 months in their cohort.  Higher antipsychotic polypharmacy point 
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prevalence has been demonstrated amongst inpatients within SLaM, with rates falling during 
this study’s period of observation from 37% in 2007 to 16% in 2012 (Mace and Taylor, 
2015).  In contrast to higher levels of inpatient polypharmacy, a large study of both 
community and inpatient subjects within SLaM with serious mental illness (SMI) diagnoses 
(schizophrenia, bipolar affective disorder, schizoaffective disorder) estimated that 4.7% were 
prescribed long-term antipsychotic polypharmacy for at least six months (Kadra et al., 2015).     
No other studies to date have reported the prevalence of antidepressant, mood stabiliser, and 
benzodiazepine prescribing in addition to polypharmacy prior to clozapine initiation, despite 
the recognised lack of evidence for their use in addition to antipsychotics.  Studies in the 
wider population with schizophrenia identified greater use of adjuvant psychotropic 
medications; antidepressants were prescribed to 38% of patients, anxiolytics to 22%, and 
mood stabilisers to 19% in a large study carried out in the USA (Chakos et al, 2006).  An 
Austrian study further demonstrated high rates of adjuvant psychotropic medication use, but 
noted large variation in use between different clinics (Ritmannsberger et al, 1999).  
  Previous research has recognised severity of schizophrenia as a predictor of polypharmacy 
(Connolly and Taylor, 2014).  Our results partially support this, suggesting polypharmacy is 
less common in those with milder symptoms, but also less common in those with the most 
severe symptoms.  This finding could indicate a possible lowering of average CGI-S due to 
the use of polypharmacy.   
We identified six patients who were prescribed a combination of quetiapine and amisulpride, 
representing 14.3% of polypharmacy.  The evidence underlying this strategy is limited - one 
case series of six patients partially responsive to quetiapine monotherapy who exhibited a 
reduction in psychotic symptoms with the addition of amisulpride [Englisch et al., 2010].  
However, subjects within this series gained an average of 6kg and prolactin levels increased 
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four-fold with the introduction of amisulpride, highlighting the potential for increased ADRs 
with polypharmacy.   
Strengths 
As a provider of secondary mental health services within the UK National Health Service 
(NHS), SLaM has close to a 100% monopoly in providing care for those with schizophrenia 
with a catchment area containing 1.2 million people, leading to minimal selection bias.  The 
procedure to detect medication use used data from pharmacy dispensing, structured 
medication fields, as well as Natural Language processing (using the GATE application) to 
extract medications data from free-text including clinical notes, and correspondence between 
clinicians and other agencies.  The use of multiple sources of information allows for both 
high recall and precision, and additionally, the medication application has been validated 
against manual search methods.  Manual screening for eligibility was subsequently 
undertaken to ensure all subjects met the inclusion criteria for the study.  The GATE 
medication application was utilised for identifying subjects due to its high level of recall, 
whilst analysis of case notes was undertaken manually to allow for both high recall and 
precision. Studies investigating antipsychotic polypharmacy often fail to identify subjects 
who are undergoing cross-titration between antipsychotics, for whom polypharmacy is 
required in the short term to ensure adequate plasma levels of medication.  As subjects in our 
study were being ‘worked up’ for clozapine initiation, it is unlikely that many of them were 
undergoing cross-titration between other antipsychotics, minimising the effect of cross-
titration on the reported prevalence.  
Limitations 
Our study window coincided with the implementation of a quality improvement program 
within the trust that aimed to reduce polypharmacy and high dose prescribing, and the 
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effectiveness of this program means that results may not be generalizable to other trusts or 
regions (Mace and Taylor., 2015).  Prescribed medications were assessed only at a single 
time point due to the labour intensive nature of assessing full-text case notes.  Therefore, 
wWe report a point prevalence of polypharmacy prior to clozapine initiation, so and are 
unable to identify how many patients have beenwere prescribed polypharmacy on a long term 
those subjects who had been prescribed polypharmacy historically, but are currentlywere 
monotherapy immediately prior to clozapine initiation were not identified. Additionally, the 
Polypharmacy was associated only with those subjects whose average CGI-S was within the 
two middle quartiles, and not with those subjects whose average CGI-S fell into the 
uppermost quartile, representing those with the most severe psychopathology. Whilst this 
finding could indicate a possible lowering of average CGI-S due to the use of polypharmacy, 
it must be interpreted with caution due to the uncertain temporal relationship between 
polypharmacy prescription and symptom severity as it is not known for how long subjects 
were prescribed polypharmacy.      
The inclusion of patients with a diagnosis of schizoaffective disorder may have 
increasedexplain the prevalencesome cases of mood stabiliser and antidepressant use prior to 
clozapine initiation, although the prevalence of antidepressant and mood stabiliser 
prescription were around two and threefold greater than the rates of schizoaffective 
diagnoses.  Finally, Ccase notes were often unclear as to whether benzodiazepines were 
prescribed on a regular or as required basis, and as such their use may be under-reported.    
Implications  
Our findings have important implications for prescribers and future guidelines.  Our 
resultsWe show found that whilst the prevalence of polypharmacy in treatment resistant 
adults prior to clozapine therapy is was relatively low, the use of other poorly evidenced 
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adjunctive medications is was both common, and also more frequently observed, in those 
prescribed antipsychotic polypharmacy.  This observation suggests that some prescribers are 
seeking to overcome treatment resistance through the addition of further drugs to already 
unevidenced weaklypoorly evidenced regimens.  Of particular note is the marked association 
between antidepressant use and polypharmacy.  Further research is required to better 
understand whether the extent to which this relationship is due todriven by an increased 
incidence of comorbid depression in treatment resistant individuals, misdiagnosis of affective 
disorders with psychotic features, or a failure of antipsychotics to adequately treat the 
negative symptoms of schizophrenia.   
The large number of different antipsychotic combinations prescribed suggests that what little 
evidence is available rarely factors in to clinical decision making when polypharmacy is used.  
There are many factors that influence clinician’s decisions to implement polypharmacy or 
other augmentation strategies in preference to clozapine.  Both clinician’s own preferences 
and views held by patients regarding clozapine are heavily influenced by concerns 
surrounding adverse effects, adherence and required monitoring protocols, as well as a 
persisting lack of knowledge regarding clozapine’s superior efficacy (Patel., 2012). 
Polypharmacy use, whilst modest in our cohort, contributes to delay in treatment with 
clozapine.  (Howes et al., 2012) .  Longer duration of inadequately treated psychosis is 
associated with poorer outcomes, both in terms of symptoms and overall functioning (Perkins 
et al., 2005). Whilst clinicians and patients may have negative perceptions of clozapine, it is, 
for the time being at least,remains a better evidenced treatment than antipsychotic 
polypharmacy in terms of efficacy and safety.must be considered as both a more efficacious 
and probably safer option than polypharmacy.  
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